A rare disease is wreaking havoc on the U.S. healthcare system, and it’s costing hospitals and doctors big bucks.
Humana Health, the largest US pharmacy and a leading provider of pharmaceuticals, has announced a new strategy to combat the disease called the “Disease Zero Plan,” which focuses on reducing costs for healthcare providers and patients.
The new strategy is the latest move to reduce the cost of healthcare and has the potential to save hospitals millions of dollars annually.
The new plan, which is designed to help improve health outcomes for patients, aims to reduce costs for hospitals by lowering prices for pharmaceuticals that are needed to treat common diseases such as diabetes, cancer, heart disease, and infections.
According to the National Institutes of Health (NIH), the average cost of a prescription drug in 2016 was $3,400, up from $3.3 million in 2015.
Humana’s new strategy aims to help hospitals reduce the price of prescription drugs by 20% to 30%.
This could mean a savings of $400 million to $600 million a year for hospitals.
“Humana is the leading provider and retailer of pharmaceutical drugs in the U; however, we have to continue to take the lead in the fight against this epidemic,” Humana CEO Dr. Daniel K. Shuster said in a statement.
Shuster said Humana has developed a strategy to improve the overall efficiency of healthcare providers by reducing the cost and volume of pharmaceutical treatments.
He said that the new strategy “represents an important step in this fight, and we are excited to see it help our patients and their families.”
This plan comes as the U, which has been battling the virus since late March, has seen a steady decline in patients taking their medication.
The number of patients who have taken a medication has dropped by almost 30% in the past month, according to data from the National Center for Health Statistics.
In addition to the price reductions, Shuster and other senior leaders at Humana have pledged to work with other health care providers to help patients stay healthy and prevent a recurrence of COVID-19.
For example, the company will work with hospitals to increase the number of prescriptions filled and also with health care organizations to educate them about COVID treatments.
The company is also looking at ways to improve communication between healthcare providers about COV-19 treatments, as well as providing information about healthcare costs and benefits to consumers.
It’s also pledging to spend at least $1 billion on COVID prevention and care in the next two years.
While the company is looking to lower costs, it’s also investing in research and development to improve drug treatments.